AI Portfolio Summary
In 2025 Q4, TCG Crossover Management, LLC maintained a portfolio of 48 distinct positions. The most significant new addition to the portfolio was MONTE ROSA THERAPEUT, which now represents 2.40% of the total fund value. They heavily accumulated shares in TANGO THERAPEUTICS I, increasing their position by 49.5%. Conversely, TCG Crossover Management, LLC completely exited their position in PEPGEN INC.
Total Positions
48
Quarter
2025 Q4
Top Holding
ABVX (31.7%)
Top 10 Concentration
64.3%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-48 of 48
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
ABVX
ABIVAX SA AMERI...
|
Healthcare | 31.74% | 29.70% |
#1
Prev: #1
|
7.0 | no change | no change |
P
S
|
7,111,596 | $959,034,279 |
$25.80
+418.5%
|
2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
COGT
COGENT BIOSCIEN...
|
Healthcare | 6.90% | 4.80% |
#2
1
Prev: #3
|
4.8 | -930,000 | -13.7% |
P
S
|
5,868,162 | $208,437,114 |
$9.40
+269.4%
|
2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
CGON
CG ONCOLOGY INC
|
Healthcare | 5.04% | 7.27% |
#3
1
Prev: #2
|
4.0 | no change | no change |
P
S
|
3,670,206 | $152,386,953 |
$43.56
-4.1%
|
2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
TNGX
TANGO THERAPEUT...
|
Healthcare | 3.74% | 3.53% |
#4
2
Prev: #6
|
4.5 | 4,225,898 | 49.5% |
P
S
|
12,762,094 | $113,072,153 | 2022 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CNTA
CENTESSA PHARMA...
|
Healthcare | 3.55% | 3.74% |
#5
Prev: #5
|
4.4 | 1,150,000 | 36.7% |
P
S
|
4,286,480 | $107,204,865 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DYN
DYNE THERAPEUTI...
|
Healthcare | 2.99% | 2.87% |
#6
4
Prev: #10
|
2.2 | no change | no change |
P
S
|
4,615,144 | $90,272,217 | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RAPT
RAPT THERAPEUTI...
|
Healthcare | 2.89% | 2.08% |
#7
8
Prev: #15
|
4.2 | 946,133 | 57.8% |
P
S
|
2,582,408 | $87,466,159 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TYRA
TYRA BIOSCIENCE...
|
Healthcare | 2.52% | 1.99% |
#8
8
Prev: #16
|
2.0 | no change | no change |
P
S
|
2,898,103 | $76,191,128 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AMLX
AMYLYX PHARMACE...
|
Healthcare | 2.50% | 4.17% |
#9
5
Prev: #4
|
2.0 | no change | no change |
P
S
|
6,243,812 | $75,425,249 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SVRA
SAVARA INC
|
Healthcare | 2.47% | 2.17% |
#10
4
Prev: #14
|
2.0 | no change | no change |
P
S
|
12,362,205 | $74,544,096 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GLUE
MONTE ROSA THER...
|
Healthcare | 2.40% | — |
#11
Prev: #—
|
4.5 | 4,622,151 | no change |
NEW
|
4,622,151 | $72,475,328 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OCUL
OCULAR THERAPEU...
|
Healthcare | 2.31% | 3.52% |
#12
5
Prev: #7
|
1.4 | -377,001 | -6.2% |
P
S
|
5,740,231 | $69,686,404 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DNTH
DIANTHUS THERAP...
|
Healthcare | 2.29% | 3.25% |
#13
5
Prev: #8
|
1.9 | no change | no change |
P
S
|
1,676,624 | $69,093,675 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EYPT
EYEPOINT PHARMA...
|
Healthcare | 2.16% | 2.50% |
#14
2
Prev: #12
|
1.9 | no change | no change |
P
S
|
3,572,335 | $65,266,560 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GPCR
STRUCTURE THERA...
|
Healthcare | 2.12% | 1.46% |
#15
5
Prev: #20
|
1.3 | -142,143 | -13.4% |
P
S
|
920,857 | $64,045,604 | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SYRE
SPYRE THERAPEUT...
|
Healthcare | 2.06% | 0.91% |
#16
11
Prev: #27
|
3.8 | 800,000 | 72.7% |
P
S
|
1,900,582 | $62,263,066 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
FULC
FULCRUM THERAPE...
|
Healthcare | 1.97% | 2.38% |
#17
4
Prev: #13
|
1.8 | no change | no change |
P
S
|
5,250,000 | $59,377,500 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LQDA
LIQUIDIA TECHNO...
|
Healthcare | 1.95% | 1.91% |
#18
Prev: #18
|
1.8 | no change | no change |
P
S
|
1,710,084 | $58,980,797 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BHVN
BIOHAVEN LTD
|
Healthcare | 1.73% | — |
#19
Prev: #—
|
4.2 | 4,631,317 | no change |
NEW
|
4,631,317 | $52,287,569 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IMVT
IMMUNOVANT INC
|
Healthcare | 1.40% | — |
#20
Prev: #—
|
4.1 | 1,660,933 | no change |
NEW
|
1,660,933 | $42,220,917 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KOD
KODIAK SCIENCES...
|
Healthcare | 1.34% | 0.92% |
#21
5
Prev: #26
|
3.0 | 300,000 | 26.2% |
P
S
|
1,445,538 | $40,417,243 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ADCT
ADC THERAPEUTIC...
|
Healthcare | 1.33% | 0.27% |
#22
15
Prev: #37
|
3.5 | 10,000,000 | 719.3% |
P
S
|
11,390,175 | $40,207,318 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LBRX
LB PHARMACEUTIC...
|
Healthcare | 1.29% | 1.36% |
#23
1
Prev: #22
|
1.0 | -1 | -0.0% |
P
S
|
1,745,015 | $38,844,034 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XNCR
XENCOR INC
|
Healthcare | 1.24% | 1.41% |
#24
3
Prev: #21
|
1.5 | no change | no change |
P
S
|
2,452,138 | $37,542,233 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RVMD
REVOLUTION MEDI...
|
Healthcare | 1.15% | 1.00% |
#25
2
Prev: #23
|
1.5 | no change | no change |
P
S
|
436,473 | $34,765,074 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AGIO
AGIOS PHARMACEU...
|
Healthcare | 1.06% | 2.82% |
#26
15
Prev: #11
|
0.9 | -248,200 | -17.4% |
P
S
|
1,181,841 | $32,169,712 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ARVN
ARVINAS HOLDING...
|
Healthcare | 1.05% | 0.68% |
#27
3
Prev: #30
|
3.4 | 1,048,851 | 64.8% |
P
S
|
2,666,216 | $31,621,322 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RLAY
RELAY THERAPEUT...
|
Healthcare | 0.90% | 0.46% |
#28
6
Prev: #34
|
3.4 | 1,409,835 | 77.9% |
P
S
|
3,220,186 | $27,242,774 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
JANX
JANUX THERAPEUT...
|
Healthcare | 0.82% | — |
#29
Prev: #—
|
3.8 | 1,789,617 | no change |
NEW
|
1,789,617 | $24,696,715 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TRDA
ENTRADA THERAPE...
|
Healthcare | 0.71% | 0.17% |
#30
9
Prev: #39
|
3.3 | 1,503,437 | 257.0% |
P
S
|
2,088,392 | $21,468,670 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MBX
MBX BIOSCIENCES...
|
Healthcare | 0.68% | 0.56% |
#31
1
Prev: #32
|
1.3 | no change | no change |
P
S
|
650,000 | $20,501,000 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
UPB
UPSTREAM BIO IN...
|
Healthcare | 0.67% | 1.96% |
#32
15
Prev: #17
|
0.3 | -1,373,217 | -64.9% |
P
S
|
743,886 | $20,196,505 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SLN
SILENCE THERAPE...
|
Healthcare | 0.61% | 0.77% |
#33
5
Prev: #28
|
1.2 | no change | no change |
P
S
|
3,033,560 | $18,444,045 | 2022 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
URGN
UROGEN PHARMA L...
|
Healthcare | 0.56% | 0.70% |
#34
5
Prev: #29
|
1.2 | no change | no change |
P
S
|
717,347 | $16,800,267 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ALEC
ALECTOR INC
|
Healthcare | 0.52% | — |
#35
Prev: #—
|
3.7 | 10,000,000 | no change |
NEW
|
10,000,000 | $15,600,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MNPR
MONOPAR THERAPE...
|
Healthcare | 0.31% | 0.61% |
#36
5
Prev: #31
|
0.6 | -11,085 | -7.2% |
P
S
|
141,915 | $9,267,050 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AVTX
AVALO THERAPEUT...
|
Healthcare | 0.29% | 0.30% |
#37
1
Prev: #36
|
1.1 | no change | no change |
P
S
|
483,000 | $8,771,280 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MAZE
MAZE THERAPEUTI...
|
Healthcare | 0.24% | — |
#38
Prev: #—
|
3.6 | 173,816 | no change |
NEW
|
173,816 | $7,201,197 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MIRM
MIRUM PHARMACEU...
|
Healthcare | 0.16% | — |
#39
Prev: #—
|
3.6 | 62,049 | no change |
NEW
|
62,049 | $4,901,251 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LONA
Athira Pharma, ...
|
Healthcare | 0.11% | — |
#40
Prev: #—
|
3.5 | 464,398 | no change |
NEW
|
464,398 | $3,348,507 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KRRO
KORRO BIO INC
|
Healthcare | 0.11% | 0.98% |
#41
16
Prev: #25
|
1.0 | no change | no change |
P
S
|
416,301 | $3,334,571 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VTYX
VENTYX BIOSCIEN...
|
Healthcare | 0.09% | 0.05% |
#42
2
Prev: #40
|
1.0 | no change | no change |
P
S
|
316,195 | $2,855,241 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VTGN
VISTAGEN THERAP...
|
Healthcare | 0.06% | 0.47% |
#43
10
Prev: #33
|
1.0 | no change | no change |
P
S
|
2,676,580 | $1,771,628 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PEPG
PEPGEN INC
|
Healthcare | 0.00% | 0.27% |
Sold All 😨
(Was: #38) |
0.0 | -1,200,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ADVM
ADVERUM BIOTECH...
|
Healthcare | 0.00% | 0.37% |
Sold All 😨
(Was: #35) |
0.0 | -1,668,174 | -100.0% |
CLOSED
|
— | $— | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ATXS
ASTRIA THERAPEU...
|
Healthcare | 0.00% | 0.99% |
Sold All 😨
(Was: #24) |
0.0 | -2,761,861 | -100.0% |
CLOSED
|
— | $— | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IRON
DISC MEDICINE I...
|
Healthcare | 0.00% | 1.51% |
Sold All 😨
(Was: #19) |
0.0 | -465,257 | -100.0% |
CLOSED
|
— | $— | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TRML
TOURMALINE BIO ...
|
Unknown | 0.00% | 3.09% |
Sold All 😨
(Was: #9) |
0.0 | -1,311,783 | -100.0% |
CLOSED
|
— | $— | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-48 of 48 holdings